Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Những quyển sách tương tự

• A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy
  Bằng: Kremer, Joel M., et al.
  Được phát hành: (2016)
• ABT‐122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin‐17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double‐Blind Study
  Bằng: Genovese, Mark C., et al.
  Được phát hành: (2018)
• In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
  Bằng: Parmentier, Julie M., et al.
  Được phát hành: (2018)
• Phase II Study of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17A–Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate
  Bằng: Mease, Philip J., et al.
  Được phát hành: (2018)
• Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
  Bằng: Robinson, Michael F., et al.
  Được phát hành: (2020)